Rongwei Lei1
Binh Vu2
Katerina Kourentzi2
Sanam Soomro1
Adheesha N. Danthanarayana3Jakoah Brgoch3Suma Nadimpalli1
Michelle Petri4
Chandra Mohan1*†
Richard C. Willson2,5,6*†- 1Department of Biomedical Engineering, University of Houston, Houston, TX, United States
- 2William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, United States
- 3Department of Chemistry, University of Houston, Houston, TX, United States
- 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
- 5Department of Biology and Biochemistry, University of Houston, Houston, TX, United States
- 6Escuela de Medicina y Ciencias de Salud, Tecnológico de Monterrey, Monterrey, NL, Mexico
A Correction on
A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM
By Lei R, Vu B, Kourentzi K, Soomro S, Danthanarayana AN, Brgoch J, Nadimpalli S, Petri M, Mohan C and Willson RC (2022) Front. Immunol. 13:1044743. doi: 10.3389/fimmu.2022.1044743
The Conflict of interest statement was erroneously given as: “RW is a named inventor on IP covering the use of nanophosphors in lateral flow assays, and may receive income from its commercialization by Clip Health, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest”.
The correct Conflict of interest statement is “RW is a named inventor on IP covering the use of nanophosphors in lateral flow assays, and may receive income from its commercialization by Clip Health, Inc. Authors RW, KK and BV acknowledge their financial interest in Glow Nanotech which at the time was developing a different LFA technology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest”.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: lupus nephritis, nanophosphors, lateral flow assay, biomarker, diagnostic
Citation: Lei R, Vu B, Kourentzi K, Soomro S, Danthanarayana AN, Brgoch J, Nadimpalli S, Petri M, Mohan C and Willson RC (2025) Correction: A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Front. Immunol. 16:1734343. doi: 10.3389/fimmu.2025.1734343
Received: 28 October 2025; Accepted: 30 October 2025;
Published: 21 November 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Lei, Vu, Kourentzi, Soomro, Danthanarayana, Brgoch, Nadimpalli, Petri, Mohan and Willson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chandra Mohan, Y21vaGFuQGNlbnRyYWwudWguZWR1; Richard C. Willson, d2lsbHNvbkB1aC5lZHU=
†These authors share senior authorship